

**Amendments to the Specification**


Please amend the Specification to insert a new first paragraph, immediately following the title, to claim priority under 35 U.S.C. §119(e), as follows:

“This U.S. national stage application of International Application PCT/US2005/005418, filed February 18, 2005, claims priority to U.S. provisional application Serial Number 60/547,681, filed February 25, 2004.”

Furthermore, please add as a new last page of the Specification, after the Claims, the following abstract, which abstract is the same as filed with the PCT application:

**ABSTRACT**

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT<sub>2C</sub> receptor agonists for the treatment of 5-HT<sub>2C</sub> associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:



where:

R<sup>6</sup> is -C≡C-R<sup>10</sup>, -O-R<sup>12</sup>, -S-R<sup>14</sup>, or -NR<sup>24</sup>R<sup>25</sup>;

and other substituents are as defined in the specification.